About Fortress Biotech, Inc.
https://www.fortressbiotech.comFortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products.
CEO
Lindsay Allan Rosenwald
Compensation Summary
(Year 2022)
Salary $62,665
Stock Awards $798,638
All Other Compensation $880,123
Total Compensation $1,741,427
Industry Biotechnology
Sector Healthcare
Went public November 14, 2017
Full time employees 101
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 3
Return On Assets 3
Debt To Equity 1
Price To Earnings 1
Price To Book 2
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $79.51 M
52w High $12.98
52w Low $4.72
Dividend Yield 14.05%
Frequency Monthly
P/E -14.39
Volume 5.21K
Outstanding Shares 7.56M
About Fortress Biotech, Inc.
https://www.fortressbiotech.comFortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $17.63M ▲ | $18.69M ▼ | $5.85M ▼ | 33.18% ▼ | $0.13 ▼ | $12.43M ▲ |
| Q2-2025 | $16.41M ▲ | $47.95M ▲ | $15.49M ▲ | 94.35% ▲ | $0.5 ▲ | $-8.42M ▲ |
| Q1-2025 | $13.14M ▼ | $30.67M ▼ | $-10.58M ▼ | -80.55% ▼ | $-0.48 ▼ | $-20.99M ▲ |
| Q4-2024 | $15.12M ▲ | $36.66M ▲ | $-6.76M ▲ | -44.74% ▲ | $-0.37 ▲ | $-21.78M ▼ |
| Q3-2024 | $14.63M | $31.44M | $-12.87M | -87.96% | $-0.76 | $-21.07M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $86.22M ▲ | $181.41M ▲ | $116.22M ▼ | $55.86M ▲ |
| Q2-2025 | $74.39M ▼ | $159.9M ▼ | $122.51M ▼ | $43.92M ▲ |
| Q1-2025 | $91.34M ▲ | $178.07M ▲ | $145.59M ▼ | $22.25M ▼ |
| Q4-2024 | $57.26M ▼ | $144.22M ▲ | $145.87M ▲ | $22.74M ▲ |
| Q3-2024 | $58.85M | $127.08M | $139.82M | $21.16M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $8.83M ▲ | $-6.11M ▲ | $2.87M ▼ | $15.07M ▲ | $11.83M ▲ | $-6.11M ▲ |
| Q2-2025 | $-11.65M ▲ | $-27.56M ▼ | $6.09M ▲ | $4.52M ▼ | $-16.95M ▼ | $-27.56M ▼ |
| Q1-2025 | $-24.69M ▲ | $-19.56M ▼ | $1.17M ▲ | $52.14M ▲ | $33.74M ▲ | $-19.56M ▼ |
| Q4-2024 | $-26.32M ▲ | $-12.91M ▲ | $-15M ▼ | $25.81M ▲ | $-2.1M ▲ | $-12.91M ▲ |
| Q3-2024 | $-26.69M | $-20.06M | $0 | $2.71M | $-17.35M | $-20.06M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Accutane | $20.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Amzeeq | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Qbrexza | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Zilxi | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Lindsay Allan Rosenwald
Compensation Summary
(Year 2022)
Salary $62,665
Stock Awards $798,638
All Other Compensation $880,123
Total Compensation $1,741,427
Industry Biotechnology
Sector Healthcare
Went public November 14, 2017
Full time employees 101
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 3
Return On Assets 3
Debt To Equity 1
Price To Earnings 1
Price To Book 2
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0